Telavancin

Chembox new
ImageFile=Telavancin.pngImageSize=250px
IUPACName=
OtherNames=
Section1= Chembox Identifiers
CASNo=372151-71-8
PubChem=3081362
SMILES=
MeSHName=Telavancin
Section2= Chembox Properties
Formula=C₈₀H₁₀₆Cl₂N₁₁O₂₇P
MolarMass=1755.63 g/mol
Appearance=
Density=
MeltingPt=
BoilingPt=
Solubility=
Section3= Chembox Hazards
MainHazards=
FlashPt=
Autoignition=

Telavancin is a bactericidal lipoglycopeptide under trial for use in MRSA or other Gram-positive infections.

On October 19, 2007, the US Food and Drug Administration issued an approvable letter for telavancin. Its developer, Theravance, Inc. submitted a complete response to the letter, and the FDA has assigned a Prescription Drug User Fee Act (PDUFA) target date of July 21, 2008. [cite web |url=http://www.drugs.com/nda/telavancin_080306.html |title=Drugs.com, FDA Accepts for Review Response to Approvable Letter for Telavancin |accessdate=2008-03-08 |format= |work= ]

References

External links

* [http://www.theravance.com Theravance, Inc.]